Skip to content

Study on the optimal intervention scheme of reducing the conversion rate of gastric precancerous lesions by treating both stasis and toxin in traditional Chinese medicine-construction of intelligent interactive long-term follow-up information platform for gastric precancerous diseases and gastric precancerous lesions

Study on the optimal intervention scheme of reducing the conversion rate of gastric precancerous lesions by treating both stasis and toxin in traditional Chinese medicine-construction of intelligent interactive long-term follow-up information platform for gastric precancerous diseases and gastric precancerous lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104900
Enrollment
Unknown
Registered
2025-06-25
Start date
2025-07-14
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric precancerous diseases and gastric precancerous lesions Gastric precancerous diseases and gastric precancerous lesions

Interventions

Un-expose group:None

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-75 years old, gender not limited; (2) Those who meet the diagnostic criteria for gastric polyps and gastric ulcers; Those whose disease diagnosis is confirmed as atrophic gastritis with intestinal metaplasia by gastroscopy and histopathological examination of gastric mucosa; Or those diagnosed with chronic atrophic gastritis accompanied by low-grade dysplasia through gastroscopy and pathological examination. (3) Subjects who have completed the clinical studies of Topics two, three and four in the project team, or the natural cohort population of topic one with pregastric cancer diseases (gastric polyps, gastric ulcers); Or patients with precancerous lesions of gastric cancer in the natural population. (4) Patients who voluntarily signed the informed consent form

Exclusion criteria

Exclusion criteria: (1) Patients with gastric cancer or high-grade supraendothelial neoplasia of gastric mucosa were detected by gastroscopy and histopathology before enrollment; (2) Patients with severe complications such as bleeding, obstruction and other diseases; (3) Patients with severe primary diseases such as heart, lung, liver, kidney and hematopoietic system; (4) Patients with mental illness, mental retardation and language disorder who cannot describe their symptoms and cannot cooperate with the study; (5) Patients who have participated in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Evaluation of cancer conversion rate;

Secondary

MeasureTime frame
Clinical symptom information;Syndrome information;Combined medication information;Information on concurrent diseases;Information on Helicobacter pylori infection;Physical and chemical indicators of stasis toxins;

Countries

China

Contacts

Public ContactTianwen Liu

Guangdong Provincial Hospital of Traditional Chinese Medicine

tianwenliu@gzucm.edu.cn+86 135 3883 8895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026